{"id":"endostar-chemoradiotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Hematologic toxicity (anemia, leukopenia, thrombocytopenia)"},{"rate":null,"effect":"Gastrointestinal toxicity"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Radiation-related toxicity (enhanced by combination)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Endostar (rh-endostatin) is an angiogenesis inhibitor derived from the C-terminal fragment of collagen XVIII. It suppresses tumor neovascularization by inhibiting endothelial cell proliferation and migration, thereby reducing blood supply to tumors. When combined with chemoradiotherapy, it works synergistically to enhance cytotoxic effects and improve treatment outcomes.","oneSentence":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors, used in combination with chemotherapy and radiotherapy to enhance anti-tumor effects.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:40:20.986Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer (in combination with chemotherapy and/or radiotherapy)"},{"name":"Various solid tumors (as adjunctive therapy with chemoradiotherapy)"}]},"trialDetails":[{"nctId":"NCT03086681","phase":"PHASE2","title":"Endostar Combined With Concurrent Chemoradiotherapy For Locally Advanced Cervical Carcinoma","status":"COMPLETED","sponsor":"Yong Zhang,MD","startDate":"2017-04-20","conditions":"Cervical Carcinoma","enrollment":120},{"nctId":"NCT05879796","phase":"","title":"Envafolimab Combined With Endostar and Concurrent Chemoradiotherapy for Locally Advanced Primary Cervical Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2023-05-16","conditions":"Cervical Cancer","enrollment":30},{"nctId":"NCT02237924","phase":"PHASE2","title":"Endostar Combined With Intensity-modulated Radiotherapy Compare With Chemoradiation for Nasopharyngeal Carcinoma","status":"COMPLETED","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2014-09","conditions":"Nasopharyngeal Carcinoma","enrollment":120},{"nctId":"NCT04613284","phase":"PHASE4","title":"Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2020-12-01","conditions":"Lung Cancer","enrollment":97},{"nctId":"NCT04164797","phase":"PHASE4","title":"Study of Endostar Combined With TP Regimen for Esophageal Cancer","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Xi'an Jiaotong University","startDate":"2019-11-25","conditions":"Patients With Esophageal Cancer(Ⅱ-Ⅲ)","enrollment":402},{"nctId":"NCT04161352","phase":"","title":"Endostar Combined With Concurrent Radiochemotherapy for Treatment of Unresectable Stage III NSCLC","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-11-25","conditions":"Unresectable Stage III NSCLC","enrollment":500},{"nctId":"NCT04121975","phase":"PHASE2","title":"CCRT Combined With Endostar for the Treatment of Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2019-08-01","conditions":"Cervical Cancer","enrollment":82},{"nctId":"NCT03932266","phase":"PHASE2","title":"Endostar Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregional Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Jiangsu Cancer Institute & Hospital","startDate":"2019-06","conditions":"Nasopharyngeal Carcinoma","enrollment":73},{"nctId":"NCT03622827","phase":"PHASE2","title":"Postoperative Concurrent Chemoradiotherapy Combined With Endostar for High-risk Early Stage Cervical Cancer","status":"UNKNOWN","sponsor":"Nanjing Medical University","startDate":"2018-07-31","conditions":"Uterine Cervical Neoplasms","enrollment":120},{"nctId":"NCT03588494","phase":"PHASE2, PHASE3","title":"Endostar in Combination With Chemoradiotherapy in Patient With Advanced Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Affiliated Hospital of North Sichuan Medical College","startDate":"2018-08-01","conditions":"Quality of Life","enrollment":318},{"nctId":"NCT02907710","phase":"PHASE3","title":"Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"First Affiliated Hospital of Guangxi Medical University","startDate":"2016-10","conditions":"Nasopharyngeal Carcinoma","enrollment":300},{"nctId":"NCT01218594","phase":"PHASE2","title":"Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2009-05","conditions":"Non-small Cell Lung Cancer","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"endostar+chemoradiotherapy","genericName":"endostar+chemoradiotherapy","companyName":"Second Affiliated Hospital of Xi'an Jiaotong University","companyId":"second-affiliated-hospital-of-xi-an-jiaotong-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Endostar is a recombinant human endostatin that inhibits angiogenesis by blocking new blood vessel formation in tumors, used in combination with chemotherapy and radiotherapy to enhance anti-tumor effects. Used for Non-small cell lung cancer (in combination with chemotherapy and/or radiotherapy), Various solid tumors (as adjunctive therapy with chemoradiotherapy).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}